Picture of Medincell SA logo

MEDCL Medincell SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+5.33%
3m+35.88%
6m+23.99%
1yr+0.48%
Volume Change (%)
10d/3m-45.61%
Price vs... (%)
52w High-14.38%
50d MA+12.18%
200d MA+31.82%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-69.68%
Return on Equityn/a
Operating Margin-197.01%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Medincell SA EPS forecast chart

Profile Summary

Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.

Directors

Last Annual
March 31st, 2023
Last Interim
September 30th, 2023
Incorporated
November 22nd, 2002
Public Since
October 8th, 2018
No. of Employees
138
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
28,719,999

MEDCL Share Price Performance

Upcoming Events for MEDCL

Full Year 2024 Medincell SA Earnings Release

Similar to MEDCL

Picture of AB Science SA logo

AB Science SA

fr flag iconEuronext - Paris

Picture of Advicenne SA logo

Advicenne SA

fr flag iconEuronext - Paris

Picture of Aelis Farma SA logo

Aelis Farma SA

fr flag iconEuronext - Paris

Picture of Boiron SA logo

Boiron SA

fr flag iconEuronext - Paris

Picture of DBV Technologies SA logo

DBV Technologies SA

fr flag iconEuronext - Paris

FAQ